Psychopharmacology is a powerful approach to the treatment of many psychiatric disorders. In this article I discuss the conceptual and practical issues in relation to the use of mu opioid receptor agonist, antagonist and partial agonist drugs in the treatment of opioid addiction, as this is one therapeutic area where all three types of agents are currently available. The choice of pharmacological agent is largely determined by patient profile, existence of ongoing drug misuse, and the kinetics of the drugs available. These principles, however, can be applied to other disorders as and when other pharmacological approaches become refined in these areas.
Alho H., Sinclair D., Vuori E., Holopainen A. ( 2007) Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depen88: 75-78.
2.
Bell J., Shanahan M., Mutch C., et al. (2007) A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction102: 1899-1907.
3.
Chindalore VL, Craven RA, Yu KP, Butera PG, Burns LH, Friedmann N. ( 2005) Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain6: 392-399.
4.
Clark HW ( 2003) Office-based practice and opioid-use disorders . N Engl J Med349: 928-930.
Comer SD, Sullivan MA, Yu E., et al. (2006) Injectable, sustained release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial . Arch Gen Psychiatry63: 210-218.
7.
Correia CJ, Walsh SL, Bigelow GE, Strain EC ( 2006) Effects associated with double blind omission of buprenorphine/naloxone over a 98-h period. Psychopharmacology ( Berl) 189: 297-306.
8.
Fiellin DA, Pantalon MV, Chawarski MC, et al. (2006) Counselling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med355: 365-374.
9.
Fudala PJ, Bridge TP, Herbert S., et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med349: 949-958.
10.
Gerra G., Fantoma A., Zaimovic A. ( 2006) Naltrexone and buprenorphine combination in the treatment of opioid dependence. J Psychopharmacol20: 806-814.
11.
Gorlick DA, Fiellin DA, Moore BA, Schottenfeld RS ( 2008) Counseling plus buprenorphine-naloxone for opioid dependence . N Engl J Med355: 1736-1737.
12.
Helm SII, Trescot AM, Colson J., Sehgal N., Silverman S. ( 2008) Opioid antagonists, partial agonists, and agonists/antagonists: the role of office- based detoxification. Pain Physician11: 225-235.
13.
Hulse GK, Tait RJ, Comer SD, Sullivan MA, Jacobs IG, Arnold-Reed D. ( 2005) Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend79: 351-357.
14.
Husbands SM, Sadd J., Broadbear JH, et al. (1998) 3-Alkyl ethers of clocinnamox: delayed long-term mu-antagonists with variable mu efficacy. J Med Chem41: 3493-3498.
15.
Krystal JH, Walker MW, Heninger GR ( 1989) Intermittent naloxone attenuates the development of physical dependence on methadone in rhesus monkeys. Eur J Pharmacol160: 331-338.
16.
Law F., Daglish MRC, Myles JS, Nutt DJ ( 2004) The clinical use of buprenorphine in opiate addiction: evidence and practice. Acta Neuropsychiatrica16: 246-274.
17.
Ling W., Amass L., Shoptaw S., et al. (2005) A multi-center randomized trial of buprenorphine- naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction100: 1090-1100.
18.
Legros J., Khalili-Varasteh H., Margetts G. ( 1984) Pharmacological study of pentazocine-naloxone combination: interest as a potentially non abusable oral form of pentazocine. Arch Int Pharmacodyn Ther271: 11-21.
19.
Martin WR, Jasinski DR, Mansky PA ( 1973) Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. Arch Gen Psychiatry28(6): 784-791. PMID: 4707988 [PubMedindexed for MEDLINE].
20.
Melichar JK, Myles JS, Eap CB, Nutt DJ ( 2003a) Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge test. Addict Biol8: 59-66.
21.
Melichar JK, Nutt DJ, Malizia AL ( 2003b) Naloxone displacement at opioid receptor sites measured in vivo in the human brain. Eur J Pharmacol459: 217-219.
22.
Melichar JK, Hume SP, Williams TM, et al. (2005) Using [11C]Diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. J Pharm Exp Ther312: 309-315.
23.
Milroy C., Forrest A. ( 2000) Methadone deaths: a toxicological analysis. J Clin Pathol53: 277-281.
24.
Mintzer IL, Eisenberg M., Terra M., MacVane C., Himmelstein DU, Woolhandler S. ( 2007) Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med5: 146-150 (Available at: www.pubmedcentral. nih.gov/picrender.fcgi?artid=1838690 & blobtype=pdf).
25.
Nutt DJ ( 1997) Receptor pharmacology of buprenorphine. Buprenorphine-a substitution agent for the treatment of opioid addiction: a UK perspective . Res Clin Forums9-15.
26.
Nutt JG, Jasinski DR ( 1974) Methadone-naloxone mixtures for use in methadone maintenance programs. I. An evaluation in man of their pharmacological feasibility . II. Demonstration of acute physical dependence. Clin Pharmacol Ther. Feb;15(2):156-66.
27.
Pettinati HM, O’Brien CP, Rabinowitz AR, et al. (2006) The status of naltrexone in the treatment of alcohol dependence: Specific effects on heavy drinking. J Clin Psychopharmacol26: 610-625.
28.
Poklis A. ( 1984) Decline in abuse of pentazocine/tripelennamine (T’s and Blues) associated with the addition of naloxone to pentazocine tablets . Drug Alcohol Depend14: 135-140.
29.
Ray LA, Hutchison KE ( 2007) Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response. a double-blind placebo-controlled study . Arch Gen Psychiatry64: 1069-1077.
30.
Reed DA, Schnoll SH ( 1986) Abuse of pentazocine-naloxone combination. JAMA256: 2562-2564.
31.
Srisurapanont M., Jarusuraisin N. ( 2005) Opioid antagonists for alcohol dependence. Cochrane Database Syst RevCD001867.
32.
Stoller KB, Bigelow GE, Walsh SL, Strain EC ( 2001) Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology154: 230-242.
